Increased gut permeability, inflammation, and colonic α-synuclein pathology are present in early Parkinson's disease (PD) and have been proposed to contribute to PD pathogenesis. Peptidoglycan is a structural component of the bacterial cell wall. Peptidoglycan recognition proteins (PGRPs) risk of inflammatory bowel disease. 21 We hypothesized that variation in PGLYRP genes might affect the risk of PD and tested this hypothesis in two independent study populations.
maintain healthy gut microbial flora by regulating the immune response to both commensal and harmful bacteria. We tested the hypothesis that variants in genes that encode PGRPs are associated with PD risk. Participants in two independent case-control studies were genotyped for 30 singlenucleotide polymorphisms (SNPs) in the four PGLYRP genes. Using logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) adjusted for potential confounding variables, we conducted analyses in each study, separately and pooled. One SNP failed the assay, and three had little to no variation. The ORs were similar in both study populations. In pooled analyses, three of seven PGLYRP2 SNPs (rs3813135, rs733731, rs892145), one of five PGLYRP3 SNPs (rs2987763), and six of nine PGLYRP4 SNPs (rs10888557, rs12063091, rs3006440, rs3006448, rs3006458, and rs3014864) were significantly associated with PD risk. Association was strongest for PGLYRP4 5'untranslated region (UTR) SNP rs10888557 (GG reference, CG OR 0.6 [95%CI 0.4-0.9], CC OR 0.15 [95%CI 0.04-0.6]; log-additive P-trend, 0.0004). Common variants in PGLYRP genes are associated with PD risk in two independent studies. These results require replication, but they are consistent with hypotheses of a causative role for the gut microbiota and gastrointestinal immune response in PD.
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Parkinson's disease; peptidoglycan; PGLYRP; microbiome; gut Parkinson's disease (PD) is now thought of as a systemic disorder. Non-motor symptoms such as hyposmia and constipation sometimes precede motor symptoms by years to decades, [1] [2] [3] [4] and associated α-synuclein pathology in the autonomic and enteric nervous systems may precede development of pathological conditions in the brain. [5] [6] [7] [8] Some have proposed that PD begins in the gut and moves to the brain by one of several possible mechanisms. These include retrograde axonal transport of a toxic or infectious agent, [9] [10] [11] neuron-to-neuron transmission of α-synuclein protein aggregates, 6, 12, 13 or a prion-like seeding process. 14, 15 The gut has the largest mucosal surface of the body and is thus a primary anatomic target for exposure to toxicants and infectious agents. Recent reports suggest that patients with early PD may manifest increased intestinal permeability, bacterial invasion, and high levels of inflammatory cytokines in colonic biopsy specimens. 16, 17 The gut microbiota, comprising the trillions of organisms that line the length of the gastrointestinal tract, may play a role in PD. Systemic administration of gram-negative bacterial endotoxin (lipopolysaccharide [LPS]) activates microglia in the substantia nigra and induces progressive dopaminergic degeneration in a rodent model of parkinsonism. 18 However, little is known about possible effects of other bacterial components. Peptidoglycan is a major structural component of the bacterial cell wall that serves to protect the plasma membrane. Because it is unique to bacteria, it is recognized as foreign and binds pattern recognition receptors, potently triggering an innate immune response. 19 Humans have four peptidoglycan recognition proteins (PGRPs), highly conserved innate immunity proteins encoded by PGLYRPs 1-4, which are selectively expressed in a range of tissues and are also secreted into the gut. 20 The PGRPs modulate the immune response to advantageous and harmful gut bacteria and play a major role in the development and maintenance of a healthy commensal microbiota, 20 and variants in PGLYRP genes have recently been associated with (10%). A total of 519 case and 511 control subjects were enrolled. Blood was available for 172 control subjects, because most controls were not evaluated in person. Demographic characteristics were similar in controls with and without blood collection.
Human Subjects-FAME and SEARCH were approved by institutional review boards of all participating institutions. All participants provided written informed consent.
Data Collection
Covariate Assessments-Methods were similar in FAME and SEARCH. Trained interviewers at the Parkinson's Institute collected demographic and risk factor information by telephone. If a participant was deceased or cognitively impaired at interview, a proxy respondent was recruited. Race and ethnicity were self-reported. Use of tobacco was assessed until a reference age, defined, for cases, as age at diagnosis and, for controls, as the median age at diagnosis among cases in the corresponding sex-, state/center-, and agespecific stratum. Tobacco use was defined as smoking at least one cigarette daily for 6 months or longer before reference age.
Genotyping-DNA was extracted from venous blood. 27 A custom Illumina GoldenGate array was designed using a candidate gene approach that included 1536 single-nucleotide polymorphisms (SNPs) across 132 genes. We selected tag SNPs enriched with nonsynonymous coding variants, including 8 SNPs in PGLYRP1, 8 SNPs in PGLYRP2, 5 SNPs in PGLYRP3, and 9 SNPs in PGLYRP4. Genotyping was conducted by the genomics core at the University of California, San Francisco. Clustering of calls was manually reviewed while blinded to disease status. Subjects with call rates of less than 0.93 were excluded from analyses.
Statistical Analyses
We compared subject characteristics within and between study populations using Fisher's exact test or Pearson's chi-square statistic for categorical data and independent t tests or Mann-Whitney-Wilcoxon rank-sum tests for continuous data. We used Pearson's chi-square statistic to test deviation from Hardy-Weinberg equilibrium in controls. Associations between PGLYRP SNPs and PD were assessed using unconditional logistic regression. To control for potential confounding, we included reference age (tertile), sex, state (for FAME), race/ethnicity (non-Hispanic white or other), and cigarette smoking in all models. Most FAME participants were non-Hispanic white (97%), so we considered six subjects with missing race/ethnicity to be non-Hispanic white. SEARCH had a higher proportion of nonwhite subjects (12%), so we excluded three participants with missing race/ethnicity. In constructing the model for the pooled data, we first assessed whether each cova-riate's effect differed between study populations using a chi-square test. 28 Only for smoking was heterogeneity indicated (P <0.20); consequently, we included an interaction term for smoking by study in the pooled model. We also performed analyses in men and women separately, and sensitivity analyses restricted to non-Hispanic whites and excluding case subjects with a history of PD in a first-degree relative.
Genotype was modeled for each SNP by including indicator variables for the number of minor alleles, with major allele homozygotes (no minor alleles) as the reference category. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for each genotype. Pvalues for trend (0, 1, or 2 minor alleles) were calculated assuming a log-additive relationship. Linkage disequilibrium (LD) between SNPs was calculated using Haploview v4.2 29 and is expressed as r 2 . We used multiple Web-based bioinformatics tools to predict SNP functional effects, including PROVEAN 30 (http://provean.jcvi.org/index.php), PolyPhen (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) (http:// genetics.bwh.harvard.edu/pph2/dokuwiki/start), 31, 32 TANGO, and FOLDX (http:// snpeffect.switchlab.org). 33, 34 All other analyses were conducted with SPSS v21.0 (IBM, Armonk, NY, USA).
Results
DNA was available for 100 case and 371 control subjects in FAME, and 418 case and 172 control subjects in SEARCH. Ten subjects with genotype call rates less than 0.93 were excluded from analyses (1 case and 7 controls in FAME, 2 controls in SEARCH). Complete genotyping and covariate data were available for 95 cases and 353 controls in FAME, and 385 cases and 157 controls in SEARCH. Demographic characteristics were similar in subjects with and without complete data (data not shown). Compared with FAME, SEARCH participants were more likely to be female and non-white (Table 1) . At enrollment, FAME cases had a longer PD duration than SEARCH cases (7.3 vs. 2.8 years) and were approximately 4 years older, but reference age was similar. Smoking was less common among cases than controls in both studies, although differences were greater in FAME than in SEARCH.
The PGLYRP allele frequencies were comparable in both studies, and all SNPs satisfied Hardy-Weinberg equilibrium ( Table 2 ). The rs2304200 in PGLYRP2 failed the assay; call rates for all other SNPs exceeded 99%. Three SNPs in PGLYRP1 had allele frequencies less than 1% (rs13343537, rs28722714, rs7245473) and were excluded from analyses.
None of five PGLYRP1 SNPs was associated with PD risk in FAME, SEARCH, or in pooled analyses. In pooled analyses, three of seven PGLYRP2 SNPs (rs3813135, rs733731, rs892145), one of five PGLYRP3 SNPs (rs2987763), and six of nine PGLYRP4 SNPs (rs10888557, rs12063091, rs3006440, rs3006448, rs3006458, rs3014864) were significantly associated with PD risk (Table 3 ). Odds ratios were of similar magnitude in FAME and SEARCH for all associated SNPs; and, for most SNPs, minor alleles were associated with reduced risk of PD. Evidence of association was strongest for PGLYRP4 SNPs rs10888557 (pooled P-trend, 0.0004; significant in both FAME and SEARCH), rs12063091 (pooled Ptrend, 0.009; significant in SEARCH), and rs3014864 (pooled P-trend, 0.008; significant in SEARCH). Analyses of two-and three-marker haplotypes did not identify any stronger associations than did analyses of single SNPs. Results were similar in sex-specific strata and in analyses limited to non-Hispanic whites, and in analyses that excluded subjects with a family history of PD. Age at PD diagnosis did not differ by genotype for any associated SNP in either study-specific or pooled analyses (data not shown).
Significant SNPs in PGLYRP2 were highly correlated with one another (Fig. 1) . In contrast, LD varied among significant SNPs in PGLRYP4, which spanned approximately 35,000 base pairs and included the 5' untranslated region (UTR), 3' UTR, and nonsynonymous coding SNPs. Among significantly associated nonsynonymous coding SNPs, the PGLYRP2 M270K amino acid substitution conferred by rs892145 was predicted to have a probable functional effect by Poly-Phen and TANGO (decreased aggregation tendency), whereas FOLDX predicted PGLYRP4 V213I (rs12063091) to have slightly enhanced stability. Effects of the synonymous coding and noncoding SNPs on protein expression or function are unknown, but the significantly associated SNPs rs2987763 (PGLYRP3), and rs10888557 and rs3014864 (PGLYRP4) are located near transcription factor binding sites.
Discussion
Parkinson's disease risk was associated with common variants in PGLYRP2, PGLYRP3, and PGLYPR4, which encode three of the four PGRPs. Although most associations were not statistically significant in the smaller FAME study, ORs were very similar in FAME and SEARCH, and several were significant in pooled analyses. For most SNPs, minor allelic variants were inversely associated with PD risk, with log additive effects.
Among the three significantly associated PGLYRP2 coding SNPs that were in strong LD, only rs892145 was predicted to have a high probability of conferring a functional change. However, data on predicted functional effects are limited, and functional changes that might underlie the observed risk associations could result from variability elsewhere in the gene. Associated SNPs in PGLYRP3 and PGLYRP4 are located in coding, 3'UTR and 5'UTR regions, and LD was more variable, suggesting that functional effects also may result from altered transcription. However, limited sample size and low SNP density preclude drawing conclusions regarding a direct functional role for any of the associated SNPs. We are not aware of any prior reports of PGLYRP genes and PD. Among genome-wide association studies (GWAS) in the publicly accessible GWAS Central database (http:// www.gwascentral.org/index), Maraganore et al. assessed eight markers in or near PGLYRP3 and PGLYRP4, and a single marker in PGLYRP2, none of which were associated with PD, 35 but the SNPs we studied were not included in their assay.
The PGRPs bind both gram-negative and gram-positive bacterial peptidoglycan 19 and are also able to recognize and bind LPS to a lesser extent. 36 PGLYRP1, 3, and 4 are directly bactericidal, 37 whereas PGLYRP2 is a peptidoglycan-cleaving amidase. 38 The PGRPs function to maintain beneficial gut flora, and the high expression of PGLYRP3 and 4 in the upper gastrointestinal tract make them particularly important in this regard. Stool from Pglyrp knockout mice has a markedly altered bacterial composition, with reduced numbers of Lactobacillus/lactococcus species, and increased ability to induce inflammatory cytokine and chemokine production in cultured colonic fibroblasts. 39 In a dextran sulfate sodium mouse model of colitis, knockout of any of the four PGRPs, and especially Pglyrp3, increased mucosal permeability and tissue damage and markedly increased colonic expression of γ-interferon. This increased sensitivity was transferable between animals by stool gavage, strongly implicating PGLYRP-dependent regulation of gut flora. 39 The gut microbiota is a complex, highly evolved system comprising 100 trillion organisms. 40 As the direct interface with the external environment, it is both a product and determinant of the gut immune response, and it influences interactions with nutrients, xenobiotics, and pathogenic organisms. 41 In addition to its local immune role, the gut microbiota regulates the development and function of the immune system more broadly 42 ; alterations are associated with systemic diseases such as asthma and arthritis. 43, 44 The microbiota has also been shown to modulate brain development and striatal dopaminergic turnover, and even to affect higher cognitive function and behavior via gut-brainidirectional communication. 45, 46 Although no evidence has been found to suggest that an altered microbiome is associated with increased risk of PD, convincing data argue that the gut is affected early in the disease process and could potentially play an important causative role. 6, 9, 11 Constipation is a near universal symptom in PD 47 ; and, in prospective epidemiological studies, having less frequent bowel movements is associated with future risk of PD. [2] [3] [4] In addition, α-synuclein pathological conditions are found throughout the myenteric nervous system in individuals with PD or incidental Lewy bodies. 6, 8, [48] [49] [50] Importantly, it has been observed in colon biopsy specimens obtained from patients with early PD, 8, 51 and even before disease onset. 7 Paralleling observations in Pglyrp-knockout animal models, relative to controls, PD patients manifest small intestinal bacterial overgrowth, 52 increased intestinal permeability, mucosal bacterial invasion and oxidative damage, and greater colonic expression of γ-interferon messenger RNA as well as TNF-α, IL-6, and IL-1b. 16, 17 Taken together, these data support a central role for the gut in PD pathogenesis, and findings are consistent with a disrupted gut flora and immune response, as seen in Pglyrp knockout animal models. Thus, altered PGRP expression or function could be a causative factor in PD.
Further supporting the plausibility of a causative role for peptidoglycan, LPS, another bacterial product that is released from gram-negative bacterial cell membranes during lysis, produces an animal model of parkinsonism. Intraperitoneal injection of LPS activates microglia and causes specific progressive loss of nigral dopaminergic neurons as well as increased sensitivity to subsequent toxic insults. 53, 54 Although a peptidoglycan model of parkinsonism has not been reported, like LPS, peptidoglycan up-regulates inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and inflammatory cytokines, and it activates microglia in culture. 55 Another possible relationship between gut immune function and PD is suggested by observations that variants in or near the LRRK2 gene are associated with increased risk of the inflammatory bowel disorder Crohn's disease, which is thought to result from a dysregulated immune response to the intestinal flora 56 and has also been associated with variants in PGLYRP genes. 21 Autosomal dominantly inherited variants in the LRRK2 gene are the most common genetic cause of PD, accounting for 1% to 2% of cases, and several polymorphic variants are also associated with modestly increased risk. 57 The mechanisms underlying LRRK2 PD are not known, but LRRK2 is highly expressed in a range of circulating and tissue-based immune cells. It is up-regulated in intestinal biopsy specimens from patients with Crohn's disease, and its expression in intestinal mucosa is markedly increased in response to bacterial pathogens and γ-interferon. 58, 59 Although its results are biologically plausible, our study had some limitations. Its relatively small size could have resulted in chance associations with PGLYRP SNPs, and we did not adjust results for multiple comparisons. Thus, P-values should be interpreted cautiously. However, we tested an a priori hypothesis, and although most associations were not significant in FAME, the magnitude and direction of associations were very similar in FAME and the much larger SEARCH population. Similar findings in two distinct populations argues against a chance association. In addition, although we adjusted for known potential confounding variables and conducted sensitivity analyses, we cannot rule out possible confounding by unrecognized factors that might be related to both PGLYRP genotype and PD risk. Finally, we were unable to adjust for population substructure because of the limited number of markers in our array; however, the study populations were relatively homogeneous, and results of analyses restricted to non-Hispanic whites were very similar.
In summary, we found that multiple common SNPs in three of the four genes encoding peptidoglycan recognition proteins, PGLYRP2, 3, and 4, were significantly associated with the risk of PD. Results were similar in two independent study populations and were significant in pooled samples. The gut is a site of early involvement in PD. Because PGRPs influence the host immune response to gut bacteria and the makeup of the gut microbiota, they could play a role in PD cause and pathogenesis. Further characterization of these mechanisms may lead to novel early approaches to delay or prevent onset of PD. b
Additionally adjusted for study, and study*smoking.
SNP, single-nucleotide polymorphism; ref, reference; OR, odds ratio; CI, confidence interval. Bold text: statistically significant result.
